


DT04 Rec'd PCT/PTO 27 SEP 2004

**Amendments to the claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound of formula (I) or a pharmaceutically acceptable salt thereof:





wherein



R<sup>1</sup> and R<sup>2</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl or R<sup>1</sup> is linked to R<sup>2</sup> to form a group (CH<sub>2</sub>)<sub>2</sub>, (CH<sub>2</sub>)<sub>3</sub> or (CH<sub>2</sub>)<sub>4</sub>;

p represents 1 or 2;


m represents an integer from 1 to 4, when m is an integer greater than 1, two R<sup>2</sup> groups may instead be linked to form a group CH<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub> or (CH<sub>2</sub>)<sub>3</sub>;

Q represents a group of formula (i), (ii), (iii) or (iv):





wherein [N] and [S] represent the attachment points for the groups



one of X and Y represents  $-\text{N}=\text{}$  and the other represents  $-\text{N}(\text{R}^5)-$ ;

$\text{R}^3$  and  $\text{R}^4$  independently represent hydrogen, halogen, cyano,  $-\text{CF}_3$ ,  $-\text{OCF}_3$ ,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkoxy,  $\text{C}_{1-6}$  alkanoyl or a group  $-\text{CONR}^6\text{R}^7$ ;

$\text{R}^{3a}$  and  $\text{R}^5$  independently represent hydrogen or  $\text{C}_{1-6}$  alkyl;

$\text{R}^6$  and  $\text{R}^7$  independently represent hydrogen or  $\text{C}_{1-6}$  alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

n and q independently represent 1 or 2;

r and s independently represent an integer from 1 to 3;

A represents a group  $-\text{Ar}^1$  or  $-\text{Ar}^2\text{Ar}^3$ ;

$\text{Ar}^1$ ,  $\text{Ar}^2$  and  $\text{Ar}^3$  independently represent an aryl group or a heteroaryl group, both of which may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy,  $\text{C}_{1-6}$  alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl,  $\text{C}_{1-6}$  alkoxy, aryl $\text{C}_{1-6}$  alkoxy,  $\text{C}_{1-6}$  alkylthio,  $\text{C}_{1-6}$  alkoxy $\text{C}_{1-6}$  alkyl,  $\text{C}_{3-7}$  cycloalkyl $\text{C}_{1-6}$  alkoxy,  $\text{C}_{1-6}$  alkanoyl,  $\text{C}_{1-6}$  alkoxycarbonyl,  $\text{C}_{1-6}$  alkylsulfonyl,  $\text{C}_{1-6}$  alkylsulfinyl,  $\text{C}_{1-6}$  alkylsulfonyloxy,  $\text{C}_{1-6}$  alkylsulfonyl $\text{C}_{1-6}$  alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkylsulfonamido,  $\text{C}_{1-6}$  alkylamido,  $\text{C}_{1-6}$  alkylsulfonamido $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkylamido $\text{C}_{1-6}$  alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamido $\text{C}_{1-6}$  alkyl, arylcarboxamido $\text{C}_{1-6}$  alkyl, aroyl, aroyl $\text{C}_{1-6}$

alkyl, arylC<sub>1-6</sub> alkanoyl, or a group CONR<sup>8</sup>R<sup>9</sup> or SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, wherein R<sup>8</sup> and R<sup>9</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;  
or solvates thereof.

2. (Original) A compound according to claim 1 which is a compound of formula E1-E16 or a pharmaceutically acceptable salt thereof.

3. (Amended) A [compound according to claim 1 or claim 2 for use in therapy] pharmaceutical composition which comprises a compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.

4. (Amended) A [compound according to claim 1 or claim 2 for use in the treatment of depression, anxiety, obesity and cognitive memory disorders] method of treating depression, anxiety, obesity and cognitive memory disorders which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.

5. (Canceled)